The site-specific transport and metabolism of tacrolimus in rat small intestine

Journal of Pharmacology and Experimental Therapeutics

Volumn 306, Issue 1, 2003, Pages 310-316

  Tamura, Shigeki ^a   Tokunaga, Yuji ^a   Ibuki, Rinta ^a   Amidon, Gordon L ^b   Sezaki, Hitoshi ^c   Yamashita, Shinji ^c  

^a ASTELLAS PHARMA INC   (Japan)

^b UNIVERSITY OF MICHIGAN   (United States)

^c SETSUNAN UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450; GLYCOPROTEIN P; KETOCONAZOLE; MIDAZOLAM; MULTIDRUG RESISTANCE PROTEIN; TACROLIMUS;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL STRAIN CACO 2; CONTROLLED STUDY; DRUG METABOLISM; DRUG PENETRATION; DRUG TRANSPORT; ENZYME INHIBITION; HUMAN; HUMAN CELL; ILEUM; JEJUNUM; NONHUMAN; PRIORITY JOURNAL; RAT; SMALL INTESTINE ABSORPTION;

ANIMALS; BIOLOGICAL TRANSPORT; CACO-2 CELLS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTESTINAL ABSORPTION; INTESTINE, SMALL; MALE; P-GLYCOPROTEIN; RATS; TACROLIMUS;

EID: 0038340961     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: 10.1124/jpet.103.050716     Document Type: Article

References (40)

1. Amidon GL, Sinko P, and Fleisher D (1988) Estimating human oral fraction dose absorbed: a correlation using rat intestinal membrane permeability for passive and carrier-mediated compounds. Pharm Res (NY) 5:651-654.
2. Armstrong VW and Oellerich M (2001) New developments in the immunosuppressive drug monitoring of cyclosporine, tacrolimus and azathiprine. Clin Biochem 34:9-16.
3. Bekersky I, Dressler D, and Mekki Q (2001) Effect of time of meal consumption on bioavailability of a single oral 5 mg tacrolimus dose. J Clin Pharmacol 41:289-297.
4. Benet LZ, Izumi T, Zhang Y, Silverman JA, and Wacher VJ (1999) Intestinal MDR transport proteins and P-450 enzymes as barriers to oral drug delivery. J Controlled Rel 62:25-31.
5. Chiou WL, Chung SM, and Wu TC (2000) Apparent lack of effect of P-glycoprotein on the gastrointestinal absorption of a substrate, tacrolimus, in normal mice. Pharm Res (NY) 17:205-208.
6. Floren LC, Bekersky I, Benet LZ, Mekki Q, Dressler D, Lee JW, Robert JP, and Hebert MF (1997) Tacrolimus oral bioavailability doubles with coadministration of ketoconazole. Clin Pharmacol Ther 62:41-49.
7. Fojo AT, Ueda K, Slamon DJ, Poplack DG, Gottesman MM, and Pastan I (1987) Expression of a multidrug-resistance gene in human tumors and tissues. Proc Natl Acad Sci USA 84:265-269.
8. Fukukawa H, Imventarza O, Venkataramanan R, Suzuki M, Zhu Y, Warty VS, Fung J, Todo S, and Starzl TE (1992) The effect of bile duct ligation and bile diversion on FK506 pharmacokinetics in dogs. Transplantation 53:722-725.
9. Hashimoto Y, Sasa H, Shimomura M, and Inui K (1998) Effects of intestinal and hepatic metabolism on the bioavailability of tacrolimus in rats. Pharm Res (NY) 15:1609-1613.
10. Higashikawa F, Murakami T, Kaneda T, Kato A, and Takano M (1999) Dose-dependent intestinal and hepatic first pass metabolism of midazolam, a cytochrome P4503A substrate with differently modulated enzyme activity in rats. J Pharm Pharmacol 51:67-72.
11. Hsing S, Gatmaitan Z, and Arias IM (1992) The function of Gp170, the multidrug-resistance gene product, in the brush border of rat intestinal mucosa. Gastroenterology 102:879-885.
12. Jain AB, Venkataramanan R, Cadoff E, Fung JJ, Todo S, Krajack A, and Starzl TE (1990) Effect of hepatic dysfunction and tube clamping on FK506 pharmacokinetics and trough concentrations. Transplant Proc 22:57-59.
13. Jusko WJ, Piekoszewski W, Klintmalm GB, Shaefer MS, Hebert MF, Piergies AA, Lee CC, Schechter P, and Mekki QA (1995) Pharmacokinetics of tacrolimus in liver transplant patients. Clin Pharmacol Ther 57:281-290.
14. Kagayama A, Tanimoto S, Fujisaki J, Kaibara A, Ohara K, Iwsaki K, Hirano Y, and Hata T (1993) Oral absorption of FK506 in rats. Pharm Res (NY) 10:1446-1450.
15. Kim RB, Wandel C, Leake B, Cvetkovic M, Fromm MF, Dempsey PJ, Roden MM, Belas F, Chaudhary AK, Roden DM, et al. (1999) Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein. Pharm Res (NY) 16:408-414.
16. Kobayashi M, Tamura K, Katayama N, Nakamura K, Nagase N, Hane T, Tutumi T, Niwa M, Tanaka H, Iwasaki K, and Kohsaka M (1991) FK506 assay past and present - characteristics of FK506 ELISA. Transplant Proc 23:2725-2729.
17. Kolars JC, Lown KS, Schmiedlin-Ren P, Ghosh M, Fang Cwrighton SA, Merion RM, and Watkins PB (1994) CYP3A gene expression in human gut epithelium. Pharmacogenetics 4:247-259.
18. Kolars JC, Stetson PL, Rush BD, Ruwart MJ, Schmiedlin-Ren P, Duell EA, Voorhees JJ, and Watkins PB (1992) Cyclosporine metabolism by P4503A in rat enterocytes - another determinant of oral bioavailability? Transplantation 53:596-602.
19. Lampen A, Christians U, Gonschior AK, Bader A, Hackbarth I, von Engelhardt W, and Sewing KF (1996) Metabolism of the macrolide suppressant tacrolimus by the pig gut mucosa in the Ussing chamber. Br J Pharmacol 117:1730-1734.
20. Lampen A, Christians U, Guengerich P, Watkins PB, Kolars JC, Bader A, Gonschior AK, Dralle H, Hackbarth I, and Sewing K (1995) Metabolism of the immunosuppressant tacrolimus in the small intestine: cytochrome P450, drug interactions and interindividual variability. Drug Metab Dispos 23:1315-1324.
21. Makhey VD, Guo A, Norris DA, Hu P, Yan JY, and Sinko PJ (1998) Characterization of the regional intestinal kinetics of drug efflux in rat and human intestine and in Caco-2 cells. Pharm Res (NY) 15:1160-1167.
22. Manez R, Martin M, Raman V, Silverman D, Jain A, Warty V, Gonzalez-pinto I, Kusne S, and Starzl TE (1994) Fluconazole therapy in transplant recipients receiving FK506. Transplantation 57:1521-1523.
23. Mekki Q, Lee C, Carrier S, Klintmalm G, Shaefer M, Burke P, and Schechter P (1994) The effect of food on oral bioavailability of tacrolimus in liver transplant patients. Clin Pharmacol Ther 53:229.
24. Obach RS and Reed-Hagen AE (2002) Measurement of Michaelis constants for cytochrome P450-mediated biotransformation reactions using a substrate depletion approach. Drug Metab Dispos 30:831-837.
25. Paine MF, Khalighi M, Fisher JM, Shen DD, Kunze KL, Marsh CL, Perkins JD, and Thummel KE (1997) Characterization of interintestinal and intraintestinal variations in human CYP3A-dependent metabolism. J Pharmacol Exp Ther 283:1552-1562.
26. Sattler M, Guengerich FP, Yun CY, Christians U, and Sweing KF (1992) Cytochrome P-4503A4 is responsible for biotransformation of FK506 and rapamycin in man and rat. Drug Metab Dispos 20:753-761.
27. Shimomura M, Masuda S, Saito H, Sakamoto S, Uemoto S, Tanaka K, and Inui K (2002) Roles of the jejunum and ileum in the first-pass effect as absorptive barriers for orally administered tacrolimus. J Surgical Res 103:215-222.
28. Shiraga T, Matsuda M, Nagase K, Iwasaki K, Noda K, Yamazake H, Shimada T, and Funae Y (1993) Metabolism of FK506, a potent immunosuppressive agent, by cytochrome P4503A enzymes in rat, dog and human liver microsomes. Biochem Pharmacol 47:727-735.
29. Starzl TE, Todo S, Fung J, Demetris AJ, Venkataramman R, and Jain A (1989) FK506 for liver, kidney and pancreas transplantation. Lancet ii:1000-1004.
30. Swaminathan A, Burckart G, and Venkataramanan R (1993) Uptake of FK506 by rat intestinal rings. Pharm Res (NY) 10:S389.
31. Taki Y, Sakane T, Nadai T, Sezaki H, Amidon GL, Langguth P, and Yamashita S (1995) Gastrointestinal absorption of peptide drug: quantitative evaluation of the degradation and the permeation of metkephamid in rat small intestine. J Pharmacol Exp Ther 274:373-377.
32. Tamura S, Ohike A, Ibuki R, Amidon GL, and Yamashita S (2002) Tacrolimus is a class II low-solubility high-permeability drug: the effect of P-glycoprotein efflux on regional permeability of tacrolimus in rats. J Pharm Sci 91:719-729.
33. Todo S, Fung J, Starzl TE, Tzakis A, Demetris AJ, Kormos R, Jain A, Alessiani M, Takaya S, and Shapiro (1990) Liver, kidney and thoracic organ transplantation under FK506. Ann Surg 212:295-302.
34. Trezise AE, Romano PR, Gill DR, Hyde SC, Sepulveda FV, Buchwald M, and Higgins CF (1992) The multidrug resistance and cystic fibrosis genes have complementary patterns of epithelial expression. EMBO (Eur Mol Bio Organ) J 11:4291-4303.
35. Venkataramanan R, Swaminathan A, Prasad T, Jain A, Zuckerman S, Warty V, Mcmichael J, Lever J, Burckart G, and Starzl T (1995) Clinical pharmacokinetics of tacrolimus. Clin Pharmacokinet 29:404-430.
36. Vincent SH, Karaman BV, Painter SK, and Chiu SH (1992) In vitro metabolism of FK506 in rat, rabbit and human liver microsomes: identification of a major metabolite and of cytochrome P4503A as the major enzymes responsible for its metabolism. Arch Biochem Biophys 294:454-460.
37. Wacher VJ, Silverman JA, Wong S, Tran-Tau P, Chan AO, Chai A, Yu XQ, O'mahony D, and Ramtoola Z (2002) Sirolimus oral absorption in rats is increased by ketoconazole but is not affected by D-α-tocopheryl poly(ethylene glycol 1000) succineta. J Pharmacol Exp Ther 303:308-313.
38. Yamashita S, Yoshida M, Taki Y, Sakane T, and Nadai T (1994) Kinetic analysis of the drug permeation process across the intestinal epithelium. Pharm Res (NY) 11:1646-1651.
39. Zhang QY, Hsieh Y, Izumi T, Lin TH, and Benet ZL (1998) Effect of ketoconazole on the intestinal metabolism, transport and oral bioavailability of K02, a novel vinylsulfone peptidomimetic cysteine protease inhibitor and a P4503A, P-glycoprotein dual substrate, in male Sprague-Dawley rats. J Pharmacol Exp Ther 287:245-252.
40. Zhang QY, Wikoff J, Dunbar D, and Kaminsky L (1996) Characterization of rat small intestinal cytochrome P450 composition and inducibility. Drug Metab Dispos 24:322-328.